Skip to content

2022 December 1 release

Compare
Choose a tag to compare
@brendanreardon brendanreardon released this 01 Dec 20:48
· 18 commits to main since this release
9148e3d

In this release, we have removed neoantigen burden as a cataloged feature type and combined Silencing with Knockdown feature types. We additionally expanded upon fields required for each feature type within our S.O.P.

Added entries:

  • (FDA) RET fusions and sensitivity to selpercatinib in any solid tumor.

Revised entries:

  • (Preclinical) PPARGC1A knockdown with CRSPR-Cas9 and not favorable prognosis in melanoma was changed from the feature type Silencing to Knockdown.
  • (Preclinical) USP11 knockdown with siRNA and sensitivity to olaparib in osteosarcoma was changed from the feature type Silencing to Knockdown.

Removed entries:

  • (Clinical evidence) High Neoantigen Burden and sensitivity to pembrolizumab in non-small cell lung cancer.